Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 4/20 | 0.64 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.55 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.55 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.55 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938743 | 0.92 | GPR183 (0.67) | GPR183 | |
| SCHEMBL17938730 | 0.90 | GPR183 (0.63) | GPR183PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17938679 | 0.87 | GPR183 (0.76) | GPR183 | |
| SCHEMBL16614498 | 0.86 | GPR183 (0.61) | GPR183L3MBTL1 | |
| SCHEMBL17938757 | 0.86 | GPR183 (0.61) | GPR183PRKAA2 | |
| SCHEMBL17938697 | 0.82 | GPR183 (0.63) | GPR183PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17938706 | 0.82 | GPR183 (0.63) | GPR183PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL16598472 | 0.81 | GPR183 (0.59) | GPR183 | |
| SCHEMBL17938766 | 0.80 | GPR183 (0.73) | GPR183SIGMAR1FAAH | |
| SCHEMBL17938710 | 0.79 | GPR183 (0.62) | GPR183FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | GPR183 22/4885PRKAB2 864/4885PRKAG1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.